Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Marubeni Expands Pharma Sales Biz into Africa with Phillips Investment
Japanese trading house Marubeni said on August 19 that it has completed an investment in Phillips Healthcare, expanding the geographic reach of its pharmaceutical sales platform to Asia, China, the Middle East, and Africa. Phillips Healthcare, a leading distributor of…
To read the full story
Related Article
- Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
- Marubeni Pharma Targets Doubling Profits by FY2035 with 2 New Deals Each Year
November 25, 2025
- Marubeni Invests in Healthcare Product Distributor in Africa
January 29, 2025
BUSINESS
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
- Drug Makers, Wholesalers Rush to Gauge Kumamoto Quake Impact
July 29, 2026
- Pfizer Brings Eisai into Nurtec Promotion in Japan
July 28, 2026
- Celltrion, Nippon Kayaku Broaden Alliance in Biopharma Biz
July 28, 2026
- Ishin Eyes Domestic Production of Allostem by August 2028
July 28, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…